Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone (SUPPRESS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01605084 |
Recruitment Status
:
Withdrawn
First Posted
: May 24, 2012
Last Update Posted
: December 4, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV | Drug: Atazanavir Drug: Darunavir Drug: Ritonavir Drug: Optimized NRTI backbone | Phase 3 |
Allocation: Randomization will be stratified
- ATV = Atazanavir
- DRV = Darunavir
- RTV = Ritonavir
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 0 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-Label Phase 3B Study in HIV-Infected Individuals With Viremia on or After Their First-Line Non-Nucleoside Reverse Transcriptase Inhibitor or Integrase Inhibitor-Based Regimen and Starting a Second-Line Regimen Consisting of ATV/RTV or DRV/RTV With an Optimized NRTI Backbone |
Study Start Date : | June 2012 |
Estimated Primary Completion Date : | August 2014 |
Estimated Study Completion Date : | August 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Arm 1: ATV/RTV 300/100 mg QD + optimized NRTI backbone |
Drug: Atazanavir
Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
Other Name: REYATAZ®
Drug: Ritonavir
Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
Other Name: NORVIR®
Drug: Optimized NRTI backbone
tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks NRTI backbone are: - Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine) The following NRTI combinations are prohibited in this study:
|
Experimental: Arm 2: DRV/RTV 800/100 mg QD + optimized NRTI backbone |
Drug: Darunavir
Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
Other Name: PREZISTA®
Drug: Ritonavir
Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
Other Name: NORVIR®
Drug: Optimized NRTI backbone
tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks NRTI backbone are: - Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine) The following NRTI combinations are prohibited in this study:
|
- Proportion of subjects with Human immunodeficiency virus 1 (HIV-1) Ribonucleic Acid (RNA) < 50 c/mL [ Time Frame: At Week 48 ]
- Proportion of subjects with HIV-1 RNA < 50 c/mL [ Time Frame: At week 24 ]
- Change from baseline in CD4 cell count [ Time Frame: Baseline (Week 0) and at week 48 ]
- Incidence rates of serious adverse event (SAEs) and adverse events (AEs) leading to discontinuation [ Time Frame: up to week 48 ]
- Incidence rates of antiretroviral resistance measured by newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failure [ Time Frame: up to week 48 ]
- Proportion of subjects with HIV-1 RNA < 50 c/mL at Week 48 by baseline M184V presence or absence [ Time Frame: Week 48 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed informed consent
-
HIV-1 infected patients with viremia (VL ≥ 500/mL) on or after their first NNRTI or INI-based cART regimen and meeting one of the two criteria below:
- On 1st line Non-nucleoside reverse transcriptase inhibitor (NNRTI) or Integrase inhibitor (INI)-based Combination antiretroviral therapy (cART) with HIV-1 RNA ≥ 500 c/ML after being on the same therapy for at least 12 weeks
- Off 1st line NNRTI or INI-based Combination antiretroviral therapy (cART) for at least 2 weeks after having been on antiviral therapy for at least 4 weeks and who are non-compliant and off first line cART without a history of virologic failure with resistance, with a : HIV-1 RNA ≥ 500 c/ML
- Fully sensitive genotype and phenotype report for Atazanavir/Ritonavir (clinical cut-off of 5.2) and Darunavir/Ritonavir (clinical cut-off ranging from 10 to 90)
- At least one NRTI other than Lamivudine (3TC) or emtricitabine (FTC) with full sensitivity (one "active" NRTI) by genotype and phenotype, ie, PhenoSense Genotype (GT), report must provide a "sensitive" net assessment of susceptibility. An NRTI or PI (reported with or without ritonavir) with a "partially sensitive" net assessment will not be considered "fully sensitive"
4. Mentally able to participate in the study 5. Men and women ≥ 18 years old
- Women of child bearing potential who engage in vaginal intercourse and who are not clinically sterilized must use highly effective methods of birth control during the study
Exclusion Criteria:
-
Screening HIV genotype showing presence at baseline of any of the following Protease inhibitor (PI) Mutation Patterns associated with genotypic resistance to Atazanavir sulfate/ Ritonavir or Darunavir/Ritonavir will lead to exclusion:
- Subjects with any darunavir associated mutations* at baseline (*V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V and L89V)
- Subjects with a major mutation to Atazanavir sulfate consisting of N88S
- Subjects with more than 3 of any of the following Atazanavir sulfate related mutations:D30N, M36I/V, M46I/L/T, I54V/L/T/M/A, A71V/T/I/G, G73S/A/C/T, V77I, V82A/F/T/S/I, I84V/A, N88D or L90M
- Subjects with < 1 fully active NRTI on PhenoSense report, other than lamivudine and emtricitabine
- Diagnosed with active tuberculosis
- Chronic hepatitis B infection
- Hepatitis C-positive patients who are not clinically stable or need treatment during the study period
- Acute hepatitis in the 30 days prior to study entry
- Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug
- Intractable diarrhea within 30 days prior to study entry
- Presence of a newly diagnosed Human immunodeficiency virus (HIV)-related opportunistic infection or any medical condition requiring acute therapy at the time of enrollment
- Subject's with Cushing's syndrome
- Untreated hypothyroidism or hyperthyroidism
- Recent therapy with agents with significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start
- Subject's with obstructive liver disease
- Active alcohol or illegal substance use
- Inability to swallow capsules
- Active peripheral neuropathy
- Presence of cardiomypathy or any significant cardiovascular disease
- Known, clinically significant cardiac conduction system disease
-
Physical and Laboratory Test Findings:
- Moderate to severe hepatic insufficiency
-
Screening laboratory values as follows:
- T4 < 4mcg/dL or >11mcg/dL and/or Thyroid-stimulating hormone (TSH) <0.5mU/L or >5.0mU/L
- Calculated creatinine clearance < 60 cc/min
- Hemoglobin < 8.0 g/dL
- Total serum lipase ≥ 1.4 times the upper limit of normal (ULN)
- Liver enzymes [Aspartate transaminase (AST), Alanine transaminase (ALT)] ≥ 5 times the ULN
- Alkaline phosphatase > 5 times the ULN
- Platelets < 50,000 cells/mm3
- Positive blood screen for hepatitis B surface antigen (HBsAg)
- Total serum bilirubin ≥ 1.5 times the ULN
-
Allergies and Adverse Drug Reaction:
- Previously demonstrated hypersensitivity to any of the components of atazanavir or the other experimental agents in this study
- Darunavir contains a sulfonamide moiety. Darunavir should be used with caution in patients with a known sulfonamide allergy
- History of allergy to atazanavir, ritonavir, or darunavir
- History of allergy to NRTIs included as NRTI backbone options in this study
- History of clinically relevant severe drug reaction
-
Sex and Reproductive Status:
- Women with a positive pregnancy test on enrollment prior to study drug administration
- Women who become pregnant during the study will be taken off-protocol
- Women using a prohibited contraceptive method
- Women who are breastfeeding
-
Other Exclusion Criteria
- Prisoners or subjects who are involuntarily incarcerated
- Subjects who are compulsorily detained for treatment of wither a psychiatric or physical illness

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01605084
United States, Arizona | |
Southwest Center For Hiv/Aids | |
Phoenix, Arizona, United States, 85006 | |
United States, Arkansas | |
Health For Life Clinic Pllc | |
Little Rock, Arkansas, United States, 72207 | |
United States, California | |
Uc Davis Medical Center | |
Sacramento, California, United States, 95817 | |
Metropolis Medical Pc | |
San Francisco, California, United States, 94109 | |
United States, Indiana | |
Indiana University Hospital | |
Indianapolis, Indiana, United States, 46202 | |
United States, Michigan | |
Be Well Medical Center | |
Berkley, Michigan, United States, 48072 | |
United States, Missouri | |
Southampton Health Center | |
St Louis, Missouri, United States, 63139 | |
United States, New Jersey | |
I.D. Care Associates | |
Hillsborourgh, New Jersey, United States, 08844 | |
Saint Michael'S Medical Center | |
Newark, New Jersey, United States, 07102 | |
United States, New York | |
James J Peters VAMC | |
Bronx, New York, United States, 10468 | |
Infectious Disease Clinic & AI | |
Bronx, New York, United States |
Study Director: | Bristol-Myers Squibb | Bristol-Myers Squibb |
Additional Information:
Responsible Party: | Bristol-Myers Squibb |
ClinicalTrials.gov Identifier: | NCT01605084 History of Changes |
Other Study ID Numbers: |
AI424-493 2011-006186-18 ( EudraCT Number ) |
First Posted: | May 24, 2012 Key Record Dates |
Last Update Posted: | December 4, 2012 |
Last Verified: | December 2012 |
Additional relevant MeSH terms:
Ritonavir Darunavir Atazanavir Sulfate Reverse Transcriptase Inhibitors HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Nucleic Acid Synthesis Inhibitors |